Intravitreal aflibercept therapy in eyes with chronic central serous chorioretihopathy: Short term results Terapia intravítrea con aflibercept en ojos con coriorretinopatía serosa central crónica: resultados a corto plazo
Archivos de la Sociedad Espanola de Oftalmologia, cilt.93, sa.7, ss.315-323, 2018 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 93 Sayı: 7
- Basım Tarihi: 2018
- Doi Numarası: 10.1016/j.oftale.2018.05.007
- Dergi Adı: Archivos de la Sociedad Espanola de Oftalmologia
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.315-323
- Anahtar Kelimeler: Aflibercept, Central macular thickness, Central serous chorioretinopathy, Vascular endothelial growth factor, Visual acuity
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objectives: To evaluate the short term efficacy and tolerability results of intravitreal aflibercept injection as a treatment option for eyes with chronic central serous chorioretinopathy (CSCR). Material and methods: A prospective longitudinal study. Ten eyes of 10 patients with chronic CSCR who had been followed for > 6 months after the first intravitreal injection of aflibercept were recruited for the study. The best corrected visual acuity (BCVA) and central macular thickness (CMT) values obtained by spectral-domain optical coherence tomography were recorded at baseline and the first, third, and sixth months after the injection. Results: The mean logMAR BCVA was 0.70 ± 0.25 at baseline. At the first, third, and sixth months after the injection, the mean logMAR BCVA were 0.39 ± 0.36, 0.32 ± 0.39, and 0.29 ± 0.34, respectively. The mean and median BCVA over the entire follow-up period was significantly improved compared with baseline BCVA (P <.05 for each one). The mean CMT was 449.30 ± 142.53 μm at baseline. It was measured as 302.60 ± 72.28 μm on the first month, 294.30 ± 72.85 μm on the third month, and 294.60 ± 83.84 μm on the sixth month after the injection. The mean and median CMT during the entire follow-up period was significantly decreased compared with baseline CMT (P <.05 for each one). None of the patients had any serious ocular or systemic side effects over the course of the study. Conclusions: Short term results of this study demonstrate that intravitreal aflibercept may be used as a treatment option to improve the BCVA and reduce the CMT in chronic CSCR.